Govt cancels registration of popular cosmetic product over misleading claims

The cancellation underscores the regulator’s strict stance against misleading cosmetic claims

US House passes Bill reauthorizing FDA rare disease incentive program

Akums and Sharda University ink MoU to bridge industry–academia gap

The primary goal of the collaboration is joint research into trending and next-generation molecules

Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Intas and IntegriMedical to launch India’s first needle-free injection system for IVF and gynaecology

Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually

Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma

The drug had previously received orphan drug designation for this rare cancer on March 31, 2025

FDA setback for Sanofi’s Tolebrutinib in progressive MS

Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity

Health Minister Nadda to launch Indian Pharmacopoeia 2026 in the first week of Jan. 2026

Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities

EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP

Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation